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We have examined the regional brain distribution of [18F]GBR 13119 (18F: fl + ,  T1/2 = 110 min), a dopamine 
uptake inhibitor, in CD-1 and C57BL/6 mice. High levels of binding are observed in the striatum of both species, with 
striatum/cerebellum ratios of 3-4 at 60 min after injection of the radiotracer. Striatum radioactivity and 
striatum/cerebellum ratios are more than 50% reduced in C57BL/6 mice treated chronically with the neurotoxin 
MPTP. We conclude mice are an appropriate model for the in vivo study of the dopamine uptake system, and that 
[~SF]GBR 13119 may be a suitable in vivo marker for degeneration of striatal dopaminergic neurons. 
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1. Introduction 
The aryl-l,4-dialk(en)ylpiperazines are a class 
of compounds which have received considerable 
attention as selective and high affinity inhibitors 
of the neuronal dopamine uptake process. Two of 
these compounds, GBR 12935 (1-[2-(diphenyl- 
methoxy)ethyl]-4-(3-phenylpropyl)piperazine) and 
GBR 12783 (1-[2-diphenylmethoxy)ethyl]-4-(3- 
phenyl-2-propenyl)piperazine) have been available 
in tritium labeled form and extensively evaluated 
both in vitro and in vivo for specificity and affin- 
ity for the dopamine transport system. Recently, it 
was reported that [3H]GBR 12935, when injected 
in vivo into NMRI  mice, did not show a regional 
brain distribution (analysis of bound radioactivity 
after tissue removal, homogenization and filtra- 
tion) consistent with dopaminergic neuron distri- 
bution (Andersen et al., 1987). These authors pro- 
* To whom all correspondence should be addressed. 
pose the presence of a 'piperazine acceptor site' to 
account for the observed uniform distribution of 
[3H]GBR 12935 in their study. However, in vivo 
studies in CD-1 mice with the closely related 
compound [3H]GBR 12783 showed specific bind- 
ing of the radiotracer to expected dopaminergic 
neuronal fields (striatum, nucleus accumbens) as 
determined by ex vivo counting or autoradiogra- 
phy (Chagraoui et al., 1987; Leroux-Nicollet and 
Costentin, 1988). 
We have recently prepared a fluorine-18 labeled 
analog, [18F]GBR 13119 (1-[(4-[lSF]fluorophenyl) 
(phenyl)methoxy)ethyl]-4-(3-phenylpropyl)piper- 
azine; Kilbourn and Haka, 1988) which differs 
from GBR 12935 in only a single radioactive 
fluorine atom (18F: f l + ,  T1/2  = 110 min). Our 
goal is the development of this compound as a 
radiopharmaceutical for the study of the dopa- 
mine uptake system in man using positron emis- 
sion tomography (PET). We have extensively 
evaluated this radiotracer in vivo in rats (Kilbourn, 
1988) and in primates (Kilbourn et al., in press) 
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and have consistently observed a regional localiza- 
tion of the radiotracer in dopaminergic neuron-rich 
brain regions (caudate/putamen, nucleus accum- 
bens, olfactory tubercle, entopeduncular nucleus, 
subthalamic nuclei, substantia nigra, ventral teg- 
mental area: determined by in vivo autoradiogra- 
phy), and this localization can be blocked in vivo 
with pharmacological doses of dopamine uptake 
inhibitors but not dopamine receptor antagonists, 
not other monoamine uptake inhibitors (nisoxe- 
tine, fluoxetine). The possible existence of a high 
affinity but non-specific binding site, and possible 
species differences of regional brain distribution 
for this class of compounds (Andersen et al., 
1987), were disturbing. We have therefore ex- 
amined the regional in vivo brain distribution of 
[18F]GBR 13119 in two species of mice (CD-1 and 
C57 BL/6), and in preliminary experiments have 
examined [18F]GBR 13119 biodistribution after 
chronic MPTP treatment of C57BL/6 mice. 
2. Materials and methods 
2.1. Drugs 
[18F]GBR 13119 was prepared by methods pre- 
viously described (Kilbourn and Haka, 1988): the 
product is obtained in high radiochemical purity 
(> 98%) and very high specific activity (> 2000 
Ci/mmol). MPTP was prepared by N-methylation 
of 4-hydroxy-4-phenylpiperidine (Aldrich Chem. 
Co.) followed by acid-catalyzed dehydration. 
2.2. Regional brain distribution of [ISF]GBR 13119 
Mice (male CD-1, 20-25 g; female C57BL/6, 
25-30 g, all from Charles River) were injected via 
the tail vein with 7-10/~Ci of [18F]GBR 13119. At 
60 min the animals were killed by decapitation, 
and the brain rapidly removed and dissected into 
regions of interest (striatum, cortex and cerebel- 
lum). Blood samples were obtained, and the re- 
mainder of the brain tissue also collected. The 
tissue samples were weighed and then counted for 
fluorine-18 in an automatic gamma counter. Data 
were calculated as %ID/g for all tissues including 
blood. 
2.3. MPTP lesioning of C57BL/ 6 mice 
Lesioning of the C57BL/6 mice was done by a 
modification of a literature procedure (Ogawa et 
al., 1985). Male mice (age 10 weeks) were treated 
twice daily for four days with 30 mg/kg s.c. of a 
solution of MPTP in saline. Unfortunately this 
regimen produced a high mortality rate, with only 
two survivors from a group of 12 animals. This 
study of [t8F]GBR 13119 uptake was performed 
4.5 weeks after the cessation of MPTP treatments. 
Animals showed no outward signs of neurological 
disorder. 
T A B L E  1 
In vivo regional  b ra in  d i s t r ibu t ion  of [18F]GBR 13119 at  60 min  af ter  i.v. in jec t ion  in to  mice  and  rats. D a t a  are g iven as means  + S.D. 
CD-1 C 5 7 B L / 6  C 5 7 B L / 6  MPTP- t r ea t ed  SD rats  b,c 
mice a mice  a 1 2 
% I D / g  
St r ia tum 2.8 +0 .11  2.9 + 0 . 9  0.63 0.93 0 .294+0 .06  
Cor tex  0.98 + 0.08 1.13 + 0.21 0.45 0.75 0.187 + 0.03 
Cerebe l lum 0.66 + 0.06 0.86 + 0.1 0.39 0.52 0.132 + 0.03 
Blood 0.89 + 0.16 0.70 + 0.14 0.49 0.56 0.035 + 0.004 
Ratios 
s t r / c e r  4 .24+0 .48  3 .35+0 .97  1.61 1.79 2.58 +0 .95  
s t r / c o r  2.98 + 0.32 2.51 _ 0.52 1.4 1.24 - 
s t r / b l o o d  3.3 +0 .58  4.4 5:2.0 1.29 1.67 - 
a N = 4; b N = 11; c d a t a  f rom K i l b o u m ,  1988. 
3. Results 
3.1. Regional brain distribution of [18F]GBR 13119 
in control mice 
The distribution of [18F]GBR 13119 in the 
brains of the two species of mice is shown in table 
1; for comparison similar results obtained in rats 
(Kilbourn, 1988) are shown. The regional distri- 
bution of [18F]GBR13119 is quite similar for rats 
and mice, with higher levels in the dopaminergic 
neuron-rich striatal tissue. Striatum to cerebellum 
ratios for both species of mice are greater than 3 
at 60 rain, higher than that found in rats. Absolute 
levels of radiotracer in mouse brain is higher than 
found with rats, most likely due to the smaller 
body mass and greater delivery of tracer to the 
brain. 
3.2. fSF]GBR 13119 distribution in MPTP-treated 
mice 
The uptake and retention of [18F]GBR 13119 in 
the two MPTP-treated C57BL/6 mice, expressed 
both as %ID/g in striatum and as striatum-to- 
cerebellum ratios, were clearly lower. Because of 
inter-subject variability in animal data, the stria- 
tum/cerebellum ratio is more reliable; as can be 
seen in table 1 there is approximately a 50% 
reduction in this ratio, as compared to controls, in 
the MPTP-treated C57BL/6 mice. 
4. Discussion 
The diarylalk(en)ylpiperazines, exemplified by 
GBR 12935, GBR 12783 and GBR 13119, are 
high affinity and very selective inhibitors of the 
dopamine uptake process and are very valuable 
tools for both in vitro and in vivo studies. In 
response to a published report of species dif- 
ferences in the binding of this class of drugs to the 
dopamine uptake site (Andersen et al., 1987), we 
examined here the regional brain distribution of 
[18F]GBR 13119 in CD-1 and C57BL/6 mice, and 
compared this data to that previously obtained in 
Sprague-Dawley rats. Contrary to the results ob- 
tained with NMRI mice (striatum/cerebellum 
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ratio of 1; Andersen et al., 1987), we find that 
regional differences in [18F]GBR 13119 uptake 
and retention are observed in both CD-1 and 
C57BL/6 mice. Striatum/cerebellum ratios are 
greater than 3 at 60 min after injection. 
Our results are consistent with the previous 
reports of regional uptake of [3H]GBR 12783 (26 
Ci/mmol) in CD-1 mice (Chagraoui et al., 1987; 
Leroux-Nicollet and Costentin, 1988). Striatum/ 
cortex ratios in CD-1 mice determined with 
[18F]GBR 13119 (2.5-3) are higher than reported 
with [3H]GBR 12783 (approximately 1.3-1.5 by 
autoradiography (Leroux-Nicollet and Costentin, 
1988); 2.1 by ex vivo counting (Chagraoui et al., 
1987)). In the development and applications of in 
vivo radiotracers, it is often assumed that levels of 
non-specific binding are uniform throughout the 
brain. Thus, binding of dopaminergic tracers in 
the cerebellum (a tissue containing few dopamin- 
ergic neurons) is taken to represent non-specific 
binding, and subtraction of radioactivity levels in 
cerebellum from levels in target tissue can be used 
to roughly estimate specific binding. By such 
calculations 70-80% of the radioactivity in the 
striatum of mice is specifically bound to the DA 
uptake system. The discrepancy between our data 
and that obtained by autoradiography with 
[3H]GBR 12783 is not easily explained; we have in 
fact previously obtained better striatum-to-cere- 
bellum ratios in rats using quantitative in vivo 
autoradiography than with ex vivo counting (Ciliax 
et al., submitted for publication). As we have used 
a markedly different type of radiotracer in our 
studies, the explanation may lie in the higher 
specific activities of [18F]GBR 13119, different 
chemical stabilities of the radioactive labels, or 
different metabolites (with different in vivo bio- 
distributions). Significantly, the striatum/cerebel- 
lum ratio obtained with [18F]GBR 13119 in CD-1 
mice continues to improve at longer time periods 
(str/cer = 4.96 at 5 h), in contrast to the decline in 
this ratio reported for [3H]GBR 12783 using a 
very similar protocol (Chagraoui et al., 1987). 
C57BL/6 mice are extremely sensitive to neu- 
rochemical poisoning with MPTP (Heikkila et al., 
1984). We therefore attempted to determine if 
[18F]GBR 13119 uptake and binding will be al- 
tered in such mice, using a chronic MPTP treat- 
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ment  regimen. In  our  hands the dose of  30 m g / k g  
s.c. (twice daily, 4 days) proved fatal to a large 
propor t ion of  the animals, and we obtained only 
two survivors f rom a group of  12. Previous at- 
tempts made in our  laboratories, using dose regi- 
mens of  30 m g / k g  (i.p. or  s.c.) for 5 days (Ogawa 
et al., 1985), had proved uniformly fatal. We have 
not  been able to determine the reasons for our  
difficulties in reproducing this animal model, but  
toxicity of  M P T P  in mice has been noted by  
others (Ricaurte et al., 1987). Nevertheless, the 
two mice which did survive the t reatment  protocol  
were then utilized in a s tudy of  [18F]GBR 13119 
brain distribution and found to exhibit signifi- 
cantly lower s t r ia tum/cerebel lum ratios (table 1). 
Previously, such M P T P  treatment effects on the 
dopamine  reuptake system of mice had been de- 
termined by in vitro analysis of  excised and ho-  
mogenized tissue, where reductions of  80% of 
[3H]mazindol binding were observed (Sundstrom 
et al., 1988). Our  results suggest that  [18F]GBR 
13119 will be a suitable radiotracer for the in vivo 
measurement  of  dopaminergic  neuron degenera- 
tion; studies to correlate levels of  [18F]GBR 13119 
binding and dopamine  concentrat ions are under-  
way. 
In  conclusion, we have examined the in vivo 
brain distribution of  [18F]GBR 13119 in CD-1 and 
C 5 7 B L / 6  mice and found that it is consistent with 
dopaminergic  neuron distribution. It is not  clear if 
the previous report  of  a lack of  regional [3H]GBR 
12935 binding in N M R I  mice is due to method-  
ological problems or if it represents a true species 
difference. Our results, however, are consistent 
with those s t r ia tum/cerebel lum ratios we have 
found in rats, and in primates using PET (Kilbourn 
et al., in press), and suggests that  mice are suitable 
subjects for in vivo studies with radiolabeled 
dopamine  uptake inhibitors, including the use of  
M P T P  treatment as an animal model  of  loss of  
dopaminergic  neurons. 
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